These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Degradation of urokinase plasminogen activator (UPA) in endometrial stromal cells requires both the UPA receptor and the low-density lipoprotein receptor-related protein/alpha2-macroglobulin receptor. Casslén B; Gustavsson B; Angelin B; Gåfvels M Mol Hum Reprod; 1998 Jun; 4(6):585-93. PubMed ID: 9665342 [TBL] [Abstract][Full Text] [Related]
26. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor. Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158 [TBL] [Abstract][Full Text] [Related]
27. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor. Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275 [TBL] [Abstract][Full Text] [Related]
28. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. Degryse B; Sier CF; Resnati M; Conese M; Blasi F FEBS Lett; 2001 Sep; 505(2):249-54. PubMed ID: 11566185 [TBL] [Abstract][Full Text] [Related]
29. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569 [TBL] [Abstract][Full Text] [Related]
30. Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility. Chazaud B; Bonavaud S; Plonquet A; Pouchelet M; Gherardi RK; Barlovatz-Meimon G Exp Cell Res; 2000 Aug; 258(2):237-44. PubMed ID: 10896774 [TBL] [Abstract][Full Text] [Related]
31. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator. Sitter T; Toet K; Quax P; Kooistra T Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120 [TBL] [Abstract][Full Text] [Related]
32. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. Stahl A; Mueller BM J Cell Biol; 1995 Apr; 129(2):335-44. PubMed ID: 7721938 [TBL] [Abstract][Full Text] [Related]
33. The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein. Croucher D; Saunders DN; Ranson M J Biol Chem; 2006 Apr; 281(15):10206-13. PubMed ID: 16459332 [TBL] [Abstract][Full Text] [Related]
34. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis. Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782 [TBL] [Abstract][Full Text] [Related]
35. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. Heegaard CW; Simonsen AC; Oka K; Kjøller L; Christensen A; Madsen B; Ellgaard L; Chan L; Andreasen PA J Biol Chem; 1995 Sep; 270(35):20855-61. PubMed ID: 7657671 [TBL] [Abstract][Full Text] [Related]
36. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex. Stefansson S; Kounnas MZ; Henkin J; Mallampalli RK; Chappell DA; Strickland DK; Argraves WS J Cell Sci; 1995 Jun; 108 ( Pt 6)():2361-8. PubMed ID: 7673355 [TBL] [Abstract][Full Text] [Related]
37. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739 [TBL] [Abstract][Full Text] [Related]
38. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
39. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation. Poliakov A; Tkachuk V; Ovchinnikova T; Potapenko N; Bagryantsev S; Stepanova V Biochem J; 2001 May; 355(Pt 3):639-45. PubMed ID: 11311125 [TBL] [Abstract][Full Text] [Related]
40. Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells. Limongi P; Resnati M; Hernandez-Marrero L; Cremona O; Blasi F; Fazioli F FEBS Lett; 1995 Aug; 369(2-3):207-11. PubMed ID: 7649259 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]